Abcam, ab283568, Anti-CGRP-I+CGRP-II antibody [EPR23804-95]

Size: 20µL / 100µL / 1mL
Anti-CGRP-I+CGRP-II antibody [EPR23804-95] (ab283568) is a rabbit monoclonal antibody detecting CGRP-I+CGRP-II in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IHC-P, IHC-Fr, ICC/IF . Suitable for Human, Mouse, Rat . - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23804-95,
Isotype:IgG,
Carrier free:No,
Reacts with:Human, Mouse, Rat,
Applications:Flow Cyt (Intra), ICC/IF, WB, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-CGRP-I+CGRP-II antibody [EPR23804-95] (ab283568) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunohistochemistry (IHC-P), Immunohistochemistry (IHC-Fr), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat samples.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl.
Discover our selection of trial-size antibodies
Other related products
We have a range of other formats of antibody clone [EPR23804-95] also available for your convenience: Biotin -
ab322855
, Alexa Fluor
ab302831
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target designated as CGRP-I and CGRP-II refers to calcitonin gene-related peptide isoforms which play key roles in various physiological functions. CGRP around 37 amino acids long has alternative names such as alpha-CGRP and beta-CGRP occurring mainly in the central nervous system and peripheral nervous tissues. These peptides are potent vasodilators integral to the modulation of blood vessel tone and immune responses. Both isoforms though small in mass allow for significant physiological impacts due to their receptor interactions.
Biological function summary
CGRP-I and CGRP-II contribute to vasodilation and pain transmission in the nervous system. Each isoform can activate specific CGRP receptors mainly located on smooth muscle cells and neurons without forming stable complexes. Their activity involves increasing intracellular cAMP levels facilitating vascular relaxation and modulating nociceptive pathways. Consequently CGRP peptides are essential for conveying pain signals and supporting neurogenic inflammation mechanisms.
Pathways
CGRP-I and CGRP-II serve critical roles in the cardiovascular and nervous system pathways. The cAMP-dependent pathway one of the essential routes of action elevates vasodilation responses where CGRP interacts with the RAMP1 protein a receptor accessory protein. Another pathway involves the modulation of pain where CGRP interacts with other neurotransmitters and proteins such as substance P and neurokinin.
CGRP-I and CGRP-II show significant associations with migraines and hypertension. These peptides through their vasodilatory capabilities and nociceptive signaling connect to migraines by interacting with proteins like RAMP1 in trigeminal neurons exacerbating migraine pathology. Furthermore CGRP's role in promoting vasodilation links to hypertension management where altered CGRP activity affects blood pressure regulation. These connections make CGRP-related pathways viable targets for therapeutic intervention.